Abstract:Respiratory syncytial virus (RSV) represents a significant health threat to infants and to elderly or immunocompromised individuals. There are currently no vaccines available to prevent RSV infections, and disease management is largely limited to supportive care, making the identification and development of effective antiviral therapeutics against RSV a priority. To identify effective chemical scaffolds for managing RSV disease, we conducted a high-throughput anti-RSV screen of a 57,000-compound library. We identified a hit compound that specifically blocked activity of the RSV RNA-dependent RNA polymerase (RdRp) complex, initially with moderate low-micromolar potency. Mechanistic characterization in an in vitro RSV RdRp assay indicated that representatives of this compound class block elongation of RSV RNA products after initial extension by up to three nucleotides. Synthetic hit-to-lead exploration yielded an informative 3D quantitative structure-activity relationship (3D-QSAR) model and resulted in analogs with more than 20-fold improved potency and selectivity indices (SIs) of >1,000. However, first-generation leads exhibited limited water solubility and poor metabolic stability. A second optimization strategy informed by the 3D-QSAR model combined with in silico pharmacokinetics (PK) predictions yielded an advanced lead, AVG-233, that demonstrated nanomolar activity against both laboratory-adapted RSV strains and clinical RSV isolates. This anti-RSV activity extended to infection of established cell lines and primary human airway cells. PK profiling in mice revealed 34% oral bioavailability of AVG-233 and sustained high drug levels in the circulation after a single oral dose of 20 mg/kg. This promising first-in-class lead warrants further development as an anti-RSV drug.

Structure-Activity Relationship of Oxacyclo- and Triazolo-Containing Respiratory Syncytial Virus Polymerase Inhibitors

Discovery of gem-Dimethyl-hydroxymethylpyridine Derivatives as Potent Non-nucleoside RSV Polymerase Inhibitors

Structure-Based Discovery of Allosteric Inhibitors Targeting a New Druggable Site in the Respiratory Syncytial Virus Polymerase

Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex

JNJ-7184, a Respiratory Syncytial Virus inhibitor targeting the connector domain of the viral polymerase.

Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives

Design, synthesis, and anti-respiratory syncytial virus potential of novel 3-(1,2,3-triazol-1-yl)furoxazine-fused benzimidazole derivatives

Mechanism and spectrum of inhibition of a 4’-cyano modified nucleotide analog against diverse RNA polymerases of prototypic respiratory RNA viruses

The mechanism and pharmacodynamics of 2-((1H-indol-3-yl)thio/sulfinyl)-N-pheny acetamide derivative as a novel inhibitor against human respiratory syncytial virus

3D-QSAR Studies of 1,2,3,9B-Tetrahydro-5h-imidazo[2,1-a]isoindol-5-ones Derivatives As RSV Fusion Inhibitors

Design and Synthesis of 2-((1H-indol-3-yl)thio)-n-phenyl-acetamides As Novel Dual Inhibitors of Respiratory Syncytial Virus and Influenza Virus A.

Mechanism of Action for Respiratory Syncytial Virus Inhibitor RSV604.

Synthesis and Antiviral Activity of a Series of Novel Quinoline Derivatives As Anti-Rsv or Anti-Iav Agents

Structural basis of paramyxo- and pneumovirus polymerase inhibition by non-nucleoside small-molecule antivirals

Interaction Between the Matrix Protein and the Polymerase Complex of Respiratory Syncytial Virus

Evaluation of Small Molecule Combinations Against Respiratory Syncytial Virus in Vitro.

Substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide Analogues Potently Inhibit Respiratory Syncytial Virus (RSV) Replication and RSV Infection-Associated Inflammatory Responses.

Design, Synthesis and Biological Evaluation of Thiazolo[3, 2-A]pyrimidine Derivatives As Novel RNase H Inhibitors

Discovery and Synthesis of GS-7682, a Novel Prodrug of a 4′-CN-4-Aza-7,9-Dideazaadenosine -Nucleoside with Broad-Spectrum Potency Against Pneumo- and Picornaviruses and Efficacy in RSV-Infected African Green Monkeys

Discovery of GS-7682, a Novel 4'-Cyano-Modified C -Nucleoside Prodrug with Broad Activity against Pneumo- and Picornaviruses and Efficacy in RSV-Infected African Green Monkeys

Fused Heterocycles Bearing Bridgehead Nitrogen As Potent Hiv-1 Nnrtis. Part 2: Discovery of Novel [1,2,4]Triazolo[1,5-A]pyrimidines Using A Structure-Guided Core-Refining Approach